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ABSTRACT 
Background/purpose: Narrowband UVB phototherapy is a common treatment modality in psoriasis and atopic 
dermatitis, but evidence of its actual effect in clinical setting is sparse. Our aim was to assess the effectiveness and 
costs of narrowband UVB phototherapy in psoriasis and atopic dermatitis in clinical setting. 
Methods: We observed 207 psoriasis patients and 144 atopic dermatitis patients in eight centers. SAPASI, PO-
SCORAD and VAS measures were used at baseline, at the end and three months after the narrowband UVB 
phototherapy course. Quality of life was measured using DLQI and costs were assessed using a questionnaire. 
Results: Both in psoriasis and in atopic dermatitis the DLQI and SAPASI/PO-SCORAD improved significantly and 
the results remained improved for at least three months in both groups. Alleviation of pruritus correlated to better 
quality of life in both patient groups. We reported slight redness and burning side-effects which were due to lack 
of MED testing. Self-administered tools proved to be useful in evaluating pruritus and severity of the disease in 
psoriasis and atopic dermatitis. Mean patient costs were 310 € and 21 hours of time, and mean costs for the 
healthcare provider were 810 €. 
Conclusion: In psoriasis, narrowband UVB is a very efficient treatment in clinical setting, whereas in atopic 
dermatitis more studies are needed to determine the best dosage. 
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INTRODUCTION 
Psoriasis and atopic dermatitis (AD) are skin diseases that deteriorate the patient’s health-related quality of life 
(HRQoL) (1-3). Both skin diseases improve with narrowband ultraviolet B (NB-UVB) phototherapy (4). In a 
controlled setting, NB-UVB was shown to improve also HRQoL of psoriasis patients (5). NB-UVB therapy is 
regarded suitable for psoriasis patients with 10% or more body surface area affected by psoriasis and/or if the 
condition has not responded to topical treatment (6-8). Outcomes of NB-UVB phototherapy in AD are less studied. 
NB-UVB was shown to improve the HRQoL of children with AD (2), and in twelve AD patients at least 50% 
reduction was found in the Scoring of Atopic Dermatitis (SCORAD) questionnaire (9). 
   Alleviation of a skin disease can be assessed using various scoring systems, which are mostly aimed for 
professionals, such as the Psoriasis Area and Severity Index (PASI) and SCORAD (10,11). Nowadays patients are 
expected to take more responsibility of their care, and various patient-oriented measures, such as the Self-
Administrated PASI (SAPASI) (12,13) and the Patient-Oriented SCORAD (PO-SCORAD) have been developed (14). 
The self-administrated measures could also empower patients. Dermatology Life Quality Index (DLQI) is an 
established measure of HRQoL (15). Both patients and professionals may take use of it. The DLQI score ranges 
from 0 to 30 and scores over 10 indicate problems in HRQoL. 
   Outcomes of randomized and strictly guided studies might differ from those achieved in clinical practice. 
Therefore, little is known about how NB-UVB works in clinical context and observational clinical studies are 
needed. The Finnish Photo-Dermatology Section updated the national guidelines of NB-UVB phototherapy in 2012. 
These include a dosing schedule for NB-UVB treatment of AD patients, and two tentative dosing schedules for 
psoriasis patients with either skin photo-type II or III– IV (16). 
   The costs of phototherapy can be significant for the healthcare sector and patients. The annual cost of UVB-
phototherapy for the healthcare provider has been estimated to be between USD 3000–4800, including outpatient 
visits and phototherapy (17,18). With lower phototherapy unit costs, and without office visit costs, phototherapy 
has been estimated to cost EUR 1105 annually (19). Indirect costs, such as time and travel costs, can be significant 
for the patient. In a Dutch study, the indirect costs were estimated to be 75% of phototherapy costs (20). In a U.S. 
study, travel costs of a three-month phototherapy course were estimated to be USD 461–2306 depending on the 
distance, and total costs including phototherapy, copayments and lost wages USD 1871–4864 (21). Phototherapy 
costs after reimbursement vary between countries due to different social systems and insurances. 
   Our observational multi-center study was aimed to verify how the ordinary NB-UVB phototherapy in public out-
patient dermatologic clinics impacts psoriasis and AD with specific emphasis on HRQoL. Since there is little data 
about the costs of NB-UVB in Finland, we calculated the costs for the healthcare provider and patients. 
 
METHODS 
This study was organized as a multi-center study and the protocol was approved by the Ethics Committee of 
Tampere University Hospital (N:o R12118). All five university hospitals of Finland and three central hospitals from 
Southern Finland participated the study (Supplement 1). The data was collected in 2012–2014. 
Patients and the narrowband UVB phototherapy course 
   Each clinic was asked to recruit at least 25 psoriasis and 25 AD patients taking advantage of arriving referrals. 
Patients in the need of NB-UVB phototherapy were considered eligible. Volunteering patients gave their informed 
consent. Subjects being pregnant or under 18 years old were excluded, and as a rule, patients with photosensitivity 
or photosensitizing drugs did not receive phototherapy. No further instructions were given on how to implement 
the phototherapy; each clinic was expected to conduct it using their best knowledge and the national guidelines. 
In our national NB-UVB guidelines, the proposed initial dose for AD is 0.20 J/cm2 with 10% increments. For 
psoriasis patients with Fitzpatrick’s skin photo-type II, the initial dose is 0.20 J/cm2 with 20% increments, and for 
psoriasis patients with photo-types III-IV, 0.30 J/cm2 with 20% increments. During phototherapy, patients could 
use their routine systemic or topical medications, which were recorded in the files by the staff together with UVB 
doses and possible side effects. 
   The phototherapies were administered using Waldmann UV 7002 cabin equipped with 42 TL-01 tubes (Schulze 
& Böhm, Brühl, Germany) in four hospitals, and Waldmann UV 7001 cabin equipped with 20 TL-01 tubes 
(Waldmann, Villingen-Schwenningen, Germany) in four hospitals. In Päijät-Häme Central Hospital the cumulative 
NB-UVB doses were also measured using personal dosimeters (VioSpor blue line Type III, BioSense, Bornheim, 
Germany). The meters detect a dose ranging from 1.5 to 90 Standard Erythema Dose (SED) and are suitable for 
measurements of artificial lamps with different spectral compositions, such as TL-01 (22). One SED is equivalent 
to an erythemal effective radiant exposure of 10 mJ/cm2 CIE (23). The dosimeters were attached to the patients’ 
wrists (24). A previously measured lamp spectrum was used for the NB-UVB dose calculations (25). 
Assessment of disease activity and HRQoL  
Patients do not routinely score their disease severity or HRQoL even if it might be useful, but we asked them to do 
so. The psoriasis patients filled in the SAPASI (12,13) and AD patients the PO-SCORAD (14) measures. Pruritus and 
disease severity were assessed globally using the Visual Analogue Scales (VAS) (26). HRQoL was assessed using 
DLQI, and the change in DLQI was the principal outcome measure (15,27). All measures were filled in three times: 
at baseline, at the end of the NB-UVB course, and three months after the course. 
Assessment of phototherapy costs 
Direct costs for the patient and the healthcare provider were assessed, but not costs of productivity losses for the 
employer. A questionnaire was used to assess time and travel costs. Travel costs were calculated using distances 
reported by the patients, between their home and the phototherapy unit, together with the number of visits related 
to phototherapy. For one-way distances less than 12.5 km, a regional bus fee of 2.5 € was applied. For distances 
beyond 12.5 km, a Social Insurance Institution of Finland reimbursement cost of 0.20 €/km was used. 
   Patients reported the average time needed for travelling and administering phototherapy. Time was not 
transformed to monetary losses, which vary depending on employment status. For example, employees and 
entrepreneurs suffer different time costs since employees can generally use their working time for health care 
visits, whereas entrepreneurs suffer monetary costs for their lost time personally. 
   The copayment charge for an outpatient visit to a tertiary level hospital in 2012 was 27.50 €. For phototherapy, 
the charge was 7.50 € per visit. Total visit costs were calculated assuming only one dermatologist’s appointment, 
prior the phototherapy course, which is the typical situation. Medication costs were not included, because these 
are compensated by a separate national insurance, which was not the focus of our study.  
   In the public sector, funding of phototherapy is based on taxing of municipalities, and the small copayment paid 
by the patient. The Finnish National Institute for Health and Welfare has published the unit costs for healthcare 
for 2011. Accordingly, the average dermatologist’s appointment fee at a tertiary hospital was 199 € and a 30-
minute nurse appointment was 34 €., ultimately charged from the municipalities.  
Sample size calculation 
The minimum size of the patient cohorts was calculated assuming that a clinically significant difference in DLQI is 
5 points, with an α-value of 0.05 and a β-value of 0.90 (28). An assumed SD of 5.5 was used (27). Accordingly, it 
was considered necessary that at least 25 psoriasis patients and 25 AD patients per hospital should complete the 
study, in order to compare results between the hospitals. 
Statistics 
Statistical comparisons between psoriasis patients and AD patients were made using the t-test, chi-square test, 
or Fisher-Freeman-Halton test. Mean changes in DLQI and disease activity during the NB-UVB phototherapy 
were assessed using the paired t-test with Hochberg’s approach for multiple comparison. The data is presented 
using mean ± SD, unless stated otherwise. Stata 15.0 (StataCorp LP; College Station, Texas, USA) statistical 
package was used for the analysis. 
  
 RESULTS 
Patients 
A total of 207 psoriasis patients and 144 AD patients completed the study. The majority of psoriasis patients were 
males (n=119, 57%), but the majority of AD patients were females (n=95, 66%) (p<0.001). The mean age of 
psoriasis patients was 51 years (range 18–77) and AD patients 34 years (range 18–79) (p<0.001). The Fitzpatrick’s 
skin photo-types I to IV were presented in frequency of 7/64/115/21 for psoriasis and 6/58/71/9 for AD patients 
(p=0.22). There were seven patients with psoriatic arthritis, and 19 patients were taking acitretin, one 
methotrexate, one etanercept and one prednisolone. Seven AD patients were taking prednisolone. The minimum 
desired number of participants of 25 was gained in only some of the hospitals, which made it impossible to 
compare the results (Supplement 1). 
Disease activity after NB-UVB phototherapy 
SAPASI depicting psoriasis severity decreased from 11.7 ± 7.4 by 8.6 units during the NB-UVB course (p<0.001). 
PO-SCORAD in AD patients decreased from the initial value of 40.4 ± 14.3 by 18.9 units (p<0.001). At the end of 
the course 29 (14%) of psoriasis patients were completely cleared, whereas only two (1.4%) of AD patients did 
so. A 75% clearance of SAPASI was observed in 109 (53%) of psoriasis patients. Respectively 25 (17%) of AD 
patients achieved 75% improvement using PO-SCORAD (Table 1). VAS depicting global disease severity and 
pruritus decreased statistically significantly in both patient groups (p<0.001). 
Quality of life after NB-UVB phototherapy 
The main outcome measure, DLQI, improved in both patient groups highly significantly during NB-UVB (Fig. 1). In 
psoriasis patients DLQI improved from its initial value of 10.1 ± 6.5 by 6.3 (p<0.001), and in AD patients from 12.9 
± 6.0 by 8.1 (p<0.001) (Table 1). 
   The initial SAPASI and PO-SCORAD showed moderate correlations to initial DLQI, r=0.47 (95% CI 0.35 to 0.58, 
p<0.001), and r=0.43 (95% CI 0.28 to 0.56, p<0.001), respectively. Initial global disease severity VAS correlated 
with DLQI at the onset of the study in both patient groups (in psoriasis r=0.54, 95% CI 0.44 to 0.63, p<0.001 and 
in AD r=0.32, 95% CI 0.16 to 0.46, p<0.001). The most important determinant of HRQoL was pruritus. In both 
patient groups the initial pruritus VAS correlated highly significantly with the initial DLQI values (in psoriasis 
r=0.58, 95% CI 0.49 to 0.66, p<0.001; and in AD r=0.45, 95% CI 0.29 to 0.59, p<0.001) (Table 1). 
Disease activity and quality of life 3 months after NB-UVB phototherapy 
Three months after the NB-UVB course, SAPASI was still decreased from the baseline value by 4.9 units (p<0.001) 
and PO-SCORAD by 16.5 units (p<0.001). VAS depicting global disease severity and pruritus were still significantly 
decreased in both patient groups (p<0.001). DLQI was still decreased in psoriasis patients by 3.8 units (p<0.001) 
and in AD patients by 8.0 units (p<0.001, Fig. 1). 
NB-UVB phototherapy course 
During the NB-UVB course, psoriasis patients received a cumulative UVB dose of 16.4 ± 8.3 J/cm2 (96.5 ± 48.4 SED) 
and AD patients 12.2 ± 5.5 J/cm2 (71.8 ± 32.4 SED). The number of NB-UVB exposures was 18 ± 4 in psoriasis 
patients and 17 ± 4 in AD patients. The NB-UVB exposures were typically given three times a week. The duration 
of phototherapy was 7.7 ± 3.4 weeks in psoriasis and 7.3 ± 2.5 in AD patients (Table 2). We analyzed the initial 
UVB doses in Päijät-Häme Central Hospital. The mean initial dose was 0.21 ± 0.04 J/cm2 in psoriasis patients (n= 
28), and 0.19 ± 0.04 J/cm2 in AD patients (n=27), being in agreement with the national guidelines. According to the 
patient records, some erythema was recorded in 66% of psoriasis patients, and severe erythema or skin burn in 
8%.  Among AD patients 61% experienced some erythema during the NB-UVB course, whereas definite burns were 
seen in 13.9% (Table 2). In addition, eight psoriasis patients reported tingling and burning, seven pruritus, three 
dryness, two headache, one blistering, one tiredness and one fever. In AD patients, nine reported dryness, eight 
pruritus, four tingling and burning, two herpes simplex and one tiredness. 
 
Personal UV dosimeters 
The mean cumulative UVB dose measured using personal dosimeters in Päijät-Häme Central Hospital was 47.3 ± 
20.9 SED in psoriasis patients (n=18) and 47.1 ± 21.6 SED in AD patients (n=13). According to the internal 
dosimeter of the Waldmann cabin, the corresponding physical non-weighted doses were 13.9 ± 6.1 J/cm2 in 
psoriasis patients (n=18) and 12.7 ± 4.3 J/cm2 in AD patients (n=13). Using a previously measured lamp spectrum, 
we calculated that these doses correspond to 81.8 SED and 74.7 SED, respectively. The calculated dose is thus 42% 
higher in psoriasis patients, and 37% higher in AD patients, than the dose measured using dosimeters. 
Phototherapy costs for the patients 
The mean one-way distance to the phototherapy unit was 15.0 km (95% CI 12.6 to 17.3 km, range 0.0 to 250 km). 
The mean cumulative travel distance per patient was 569 km (95% CI 463 to 675km, range 0.0 to 14000 km), 
which yielded a mean travel cost of 149 € (95% CI 129 to 169 €, range 40 to 2800 €). The mean time required for 
one phototherapy visit including travel time was 66 min (95% CI 61 to 72 min, range 5 to 690 min), which yielded 
a mean total phototherapy course time of 21 h (95% CI 19 h to 23 h, range 2 h to 242 h). The patients’ share of 
visit costs were on average 162 € (95% CI 159 to 166 €). The mean total patient costs including travel and 
phototherapy costs were 310 € (95% CI 289 to 331 €, range 120 to 3030 €). 
Phototherapy costs for the healthcare provider 
The societal costs of phototherapy including the dermatologist’s appointment, and phototherapy sessions 
administered by nurse, were on average 810 € (95% CI 795 to 825 €). 
 
DISCUSSION 
To our knowledge, our study is the first large scale clinically oriented study to show how NB-UVB phototherapy 
functions in the normal out-patient treatment context in psoriasis and AD. Using several outcome measures, we 
showed that NB-UVB phototherapy is an efficient regime in clinical use and improves the HRQoL of psoriasis and 
AD patients highly significantly using DLQI. This was also the primary outcome measure in this study. 
Improvement was maintained for at least three months in both groups. 
   Consistent with our study, psoriasis seems to be cleared more efficiently than AD in strictly steered intervention 
studies. Dawe at al. have shown even 100% clearance in psoriasis using NB-UVB, whereas others have shown for 
AD only moderate responses (29-31). Noteworthy the SAPASI and PO-SCORAD are not comparable. PASI and 
SAPASI measure visible signs, but SCORAD and PO-SCORAD involve subjective symptoms e.g. pruritus (12-14). 
   The global measures used in our study: the “global disease severity VAS”, the “pruritus VAS” and DLQI measure 
the outcome globally and show a highly significant improvement. The results showed that NB-UVB phototherapy 
works also clinically expectedly. A clearance of 75% or more using SAPASI and PO-SCORAD was found in 50% of 
psoriasis patients, but only in 16% of AD patients. SAPASI and PO-SCORAD showed highly significant change in 
disease severity statistically. To our surprise, pruritus was equally frequent in both patient groups, although 
pruritus has earlier been shown to affect the HRQoL more in AD patients than in psoriasis patients (32). 
   NB-UVB phototherapy is indicated when topical treatments are not sufficient. Therefore, the severity of the skin 
condition is an important denominator when assessing the outcome. In our study the average severities of the skin 
conditions were either moderately severe or severe defined as DLQI > 10, SAPASI > 10 or PO-SCORAD > 40 (Table 
1). The patients were thus high need patients and the outcome of NB-UVB can be judged as optimal in agreement 
with Patrizi et al. (33). 
   In this multi-center study, the mean cumulative NB-UVB dose was 16.4 J/cm2 in psoriasis patients and 12.2 J/cm2 
in AD patients. A subset of patients used personal UV dosimeters, which measured a mean UVB dose of 47 SED in 
psoriasis and similarly 47 SED in AD. We have earlier assessed the UVB doses of a 2-week heliotherapy with similar 
dosimeters and saw a mean cumulative dose of 30 SED in psoriasis and 43 SED in AD patients (34).  During a high 
UV season even higher UVB doses, such as 60 and 109 SED, have been demonstrated in heliotherapy (35). Thus, 
the cumulative UVB dose during NB-UVB phototherapy compares to that of a 2-week heliotherapy. 
   We were surprised of high frequency of erythema at some stages of therapy in 66% of psoriasis and 61% of AD 
patients. Definite burns were seen in 8% and 9% respectively. Mild erythema reactions were seen in 73% of 
psoriasis patients receiving NB-UVB in a strictly controlled randomized study, where the dosing was based on 
preceding Minimal Erythema Dose (MED) testing (36). However, the increments in that study were 30-40% 
initially differing from our moderate increments of 10–25%, and the treatment was given twice a week. Diffey 
(2004) has shown using modeling that clearance of psoriasis is achieved faster using higher dosing (36). According 
to other studies, NB-UVB phototherapy functions at its best close to MED (31). To our knowledge, no such data is 
available for phototherapy of AD, and further studying is warranted. 
   MED testing is rarely performed preceding phototherapy in our country, and photo-testing devices may also be 
lacking on the site. Defining the skin photo-type without MED testing is a challenge (16,38-40). Therefore, the 
photo-types may not have been classified properly in the clinics explaining erythema reactions. In addition, there 
were skin photo-type I participants, which is a deviation of our national recommendation and must be discussed 
in our clinics. International guidelines suggest MED testing and using 70% of the MED as an initial dose (41). 
Increasing the use of MED testing could decrease erythema reactions. There are also technical tools available to 
predict UV dosing objectively (42). Due to increasing number of new medicines, the use of phototherapy has 
decreased and perhaps less emphasis is put on maintaining expertise. 
   The self-administered assessment tools fulfilled their task in this study. We were especially satisfied with the 
global VAS measures and DLQI showing respective outcome as the more laborious SAPASI and PO-SCORAD. To 
empower patients, the measures should be easy to calculate and interpret. Further studies with modifications of 
VAS are warranted in this purpose.  
   A 2-week heliotherapy has been shown to improve clinical signs and HRQoL of psoriasis and AD, and the 
improved HRQoL persisted in both patient groups for up to three months. Three months after heliotherapy, SAPASI 
remained decreased by 36% and PO-SCORAD by 40% (34). Autio et al. (2002) demonstrated a 45% decrease in 
SCORAD index 3 months after a 2-week heliotherapy (43). These results are comparable with the 42% SAPASI 
decrease and 41% PO-SCORAD decrease seen in the present study. 
   The costs of NB-UVB phototherapy were lower than in previous studies (17-19,44), probably because we 
included only one dermatologist’s appointment to the calculations. Also, we did not register potential laboratory, 
pathology or hospitalization costs. Thus, our cost analysis represents the cost of an ideal NB-UVB phototherapy 
course and represents at its best the minimum cost. 
   The advantage of our study is that this was a real-life follow-up study, not just register data or a random 
questionnaire. A limitation of our study is that only few departments recruited the desired 25 patients per group. 
The low figures (Supplement 1) did not mean that there was a shortage of patients, but rather that there was not 
enough staff or time to complete the study in a busy clinic. In addition, the time cost was not transformed to 
monetary costs, and earlier studies have shown that the burden of phototherapy falls on the patient and employee, 
who both may pay marked time-related cost (45,46). 
   We were able to show that NB-UVB phototherapy works well in a normal clinical setting and both psoriasis and 
AD patients showed highly significant alleviation of their skin conditions and improvement of their HRQoL. The 
improved situation, as seen in disease scores, global measures and DLQI, was sustained in both patient groups for 
at least three months confirming that earlier research outcomes coincide with clinical outcomes. The direct costs 
of NB-UVB phototherapy are reasonable or even cheap as regards severity of the skin conditions, but the invisible 
indirect costs may alter this. 
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Figure 1 
 
 
  
 Table 1 
  Baseline Change from baseline 
  Mean (SD) 
Δ After phototherapy 
Δ 3 months after 
phototherapy 
Mean (95% CI) Mean (95% CI) 
    
Psoriasis       
   DLQI 10.1 (6.5) -6.3 (-7.0 to -5.5)*** -3.8 (-4.6 to -2.9)*** 
   SAPASI 11.7 (7.4) -8.6 (-9.6 to -7.6)*** -4.9 (-6.0 to -3.8)*** 
   VAS pruritus 4.4 (2.7) -2.9 (-3.3 to -2.5)*** -1.4 (-1.9 to -1.0)*** 
   VAS global 5.8 (2.2) -3.3 (-3.7 to -3.0)*** -2.1 (-2.4 to -1.7)*** 
Atopic dermatitis       
   DLQI 12.9 (6.0) -8.1 (-9.0 to -7.1)*** -8.0 (-9.3 to -6.8)*** 
   PO SCORAD 40.4 (14.3) -18.9 (-21.4 to -16.4)*** -16.5 (-20.0 to -12.9)*** 
   VAS pruritus 5.2 (2.4) -3.1 (-3.6 to -2.7)*** -2.5 (-3.1 to -1.9)*** 
   VAS global 5.1 (2.1) -2.9 (-3.3 to -2.5)*** -2.6 (-3.1 to -2.0)*** 
    
 
Table 2 
  Psoriasis (n = 207) Atopic dermatitis  (n = 144) p-value 
Initial NB-UVB radiation dose (J/cm2) 0.21 ± 0.04* 0.19 ± 0.04** 0.137 
Cumulative NB-UVB radiation dose (J/cm2) 16.4 ± 8.3 (3.5 – 48.5) 12.2 ± 5.5 (3.0 – 29.1) < 0.001 
Number of exposures 18 ± 4 (7 – 30) 17 ± 4 (8 – 30) 0.028 
Duration of phototherapy (weeks) 7.7 ± 3.4 7.3 ± 2.5 0.119 
Exposures per week 2/3/4 48/157/1 42/100/0 0.26 
Patients with erythema 136 88 0.44 
Patients with skin burn 17 13 0.92  
    
* Based on 28 psoriasis patients in Päijät-
Häme Central Hospital    
** Based on 27 AD patients in Päijät-Häme 
Central Hospital    
 
  
 Supplement Table 1 
  Psoriasis (n = 207)  Atopic dermatitis (n = 144)  
Turku University Hospital 45 45 
Helsinki University Central Hospital 35 29 
Oulu University Hospital 39 21 
Päijät-Häme Central Hospital 31 29 
Tampere University Hospital 20 5 
Kuopio University Hospital 12 6 
Kymenlaakso Central Hospital 12 5 
Satakunta Central Hospital 13 4 
 
 
